Categories: News

TE Connectivity to report first quarter financial results on Jan. 26, 2022

SCHAFFHAUSEN, Switzerland, Jan. 5, 2022 /PRNewswire/ — TE Connectivity Ltd. (NYSE: TEL) will report financial results for the first quarter of fiscal 2022 before trading begins on Jan. 26, 2022. The company will hold a conference call for investors at 8:30 a.m. ET. The conference call may be accessed in the following ways:

  • At TE Connectivity’s website: investors.te.com  
  • By telephone: For both “listen-only” participants and those participants who wish to take part in the question-and-answer portion of the call, the dial-in number in the United States is (888) 330-3417 and for international callers, the dial-in number is (646) 960-0804.    
  • A replay of the conference call will be available on TE Connectivity’s investor website at investors.te.com  at 11:30 a.m. ET on January 26, 2022. 

ABOUT TE CONNECTIVITY
TE Connectivity Ltd. (NYSE: TEL) is a global industrial technology leader creating a safer, sustainable, productive, and connected future. Our broad range of connectivity and sensor solutions, proven in the harshest environments, enable advancements in transportation, industrial applications, medical technology, energy, data communications, and the home. With more than 85,000 employees, including over 8,000 engineers, working alongside customers in approximately 140 countries, TE ensures that EVERY CONNECTION COUNTS. Learn more at www.te.com and on LinkedIn, Facebook, WeChat and Twitter.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/te-connectivity-to-report-first-quarter-financial-results-on-jan-26-2022-301454333.html

SOURCE TE Connectivity Ltd.

Staff

Recent Posts

Global Microscopy Market to Reach USD 10.6 Billion by 2029 driven by Healthcare Innovations | MarketsandMarkets™

CHICAGO, July 4, 2024 /PRNewswire/ -- The global microscopy market is poised for significant growth, expected…

3 hours ago

FSD Pharma Files Amended and Restated Material Change Report

Toronto, Ontario--(Newsfile Corp. - July 4, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE)…

6 hours ago

CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe

MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) -- Global biotechnology leader CSL Behring (ASX: CSL)…

6 hours ago

ICPO Foundation partners with Nuclear Medicine Research Infrastructure (NuMeRI) to establish an ICPO Collaborating Center

ICPO Center NuMeRI ICPO Foundation signed the contract with Nuclear Medicine Research Infrastructure (NuMeRI) to…

6 hours ago

Psyence Biomedical Ltd. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM)…

6 hours ago